METRIOPHARM
MetrioPharm AG is a pharmaceutical development company developing drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. They hope to achieve a healthspan expansion for patients: They want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people. MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.
METRIOPHARM
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2017-01-01
Address:
Zürich, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.metriopharm.com
Total Employee:
11+
Status:
Active
Contact:
+41 (44) 515 21 97
Total Funding:
20 M CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Apache
Similar Organizations
Purple Biotech
Purple Biotech is an innovative biopharmaceutical drug development company.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.metriopharm.com Semrush global rank: 5.85 M Semrush visits lastest month: 1.42 K
- Host name: dd23328.kasserver.com
- IP address: 85.13.151.76
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "MetrioPharm"
MetrioPharm AG – Our Company
MetrioPharm is a clinical-stage company at the forefront of developing safer and more effective treatments based on first-in-class self-regulating … See moreSee details»
MetrioPharm AG – Swiss Biotech
MetrioPharm AG, a clinical stage biopharmaceutical development company based in Zurich with a subsidiary in Berlin, Germany, has developed a platform of small molecule drug candidates …See details»
MetrioPharm - Crunchbase Company Profile & Funding
MetrioPharm AG is a pharmaceutical development company developing drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk.See details»
MetrioPharm AG – Management and Board
Christoph von Moos was elected to the Board of Directors of MetrioPharm AG for a further three years at the 17th Annual General Meeting on June 20th, 2023.See details»
MetrioPharm - LinkedIn
MetrioPharm AG is a Swiss biotech company developing first-in-class auto-regulated immune modulators targeting the pathologically dysregulated mitochondrial metabolism in macrophages.See details»
MetrioPharm Investor Relations News QII 2024
With the annual report, management and the Board of Directors of MetrioPharm AG provided an overview of the company's activities in the 2023 fiscal year. These included the EU-funded …See details»
MetrioPharm AG Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for MetrioPharm AG of Zürich, ZÃœRICH. Get the latest business insights from Dun & Bradstreet.See details»
MetrioPharm Company Profile 2024: Valuation, Investors
Information on acquisition, funding, investors, and executives for MetrioPharm. Use the PitchBook Platform to explore the full profile.See details»
MetrioPharm | LinkedIn
MetrioPharm AG is a Swiss biotech company developing first-in-class auto-regulated immune modulators targeting the pathologically dysregulated mitochondrial metabolism in macrophages.See details»
MetrioPharm (Group) - life-sciences-europe.com
May 27, 2009 · MetrioPharm AG is a Swiss biotech company developing first-in-class auto-regulated immune modulators targeting the pathologically dysregulated mitochondrial …See details»
MetrioPharm Company Profile - Office Locations, Competitors
MetrioPharm is a pharmaceutical biotech company developing therapy for chronic immune disorders. It offers self-regulating drugs against cellular oxidative stress, which is one of the …See details»
MACROPHAGE METABOLIC MODULATION - MetrioPharm
MetrioPharm AG is a clinical-stage biopharmaceutical development company based in Zurich with a subsidiary for R&D activities in Berlin, focusing on therapies againstSee details»
MetrioPharm AG - startup.ch
MetrioPharm AG: MetrioPharm AG is developing a new class of drugs for early-intervention treatment and long-term control of chronic inflammation towards the goal of reversing and …See details»
MetrioPharm - Products, Competitors, Financials, Employees ...
MetrioPharm is a clinical-stage biotechnology company focused on developing self-regulating immunomodulators for the treatment of inflammatory and infectious diseases. Use the CB …See details»
MetrioPharm — Creating an ideal target product profile
Feb 24, 2020 · MetrioPharm is a private Swiss pharmaceutical development company headquartered in Zurich, Switzerland, with R&D operations in Berlin, Germany. The company …See details»
MetrioPharm AG - VentureRadar
MetrioPharm AG is developing a new class of drugs for early-intervention treatment and long-term control of chronic inflammation towards the goal of reversing and preventing diseases of …See details»
MetrioPharm Investor Relations News QII 2022
With the Annual Report 2021, the Management and the Board of MetrioPharm AG provided an overview of the company's initiatives over the past year. MetrioPharm AG was able to …See details»
»MetrioPharm Is at a Pivot Point« - MetrioPharm-Blog
Apr 10, 2019 · MetrioPharm has a disruptive, yet realistic business model. What was the next step? I liked the data and I liked the business model but the most important factor for …See details»
MetrioPharm Investor Relations News QIII 2021
MetrioPharm Investor Relations News QIII 2024 - 2024-Sep-26. Mode of Action of MetrioPharm's Lead Molecule MP1032, MetrioPharm AG Company Calendar 2024, MetrioPharm AG informs …See details»
MetrioPharm AG – Press Releases
MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that results from its clinical trial CT-05 in hospitalised patients with …See details»